Pfizer (PFE) Reports Results of Phase 3 Study for XELJANZ (tofacitinib) in Juvenile Idiopathic Arthritis - StreetInsider.com Get link Facebook X Pinterest Email Other Apps November 17, 2019 Pfizer (PFE) Reports Results of Phase 3 Study for XELJANZ (tofacitinib) in Juvenile Idiopathic Arthritis StreetInsider.com Get link Facebook X Pinterest Email Other Apps Comments
Comments
Post a Comment